SpringWorks Therapeutics

11 articles with SpringWorks Therapeutics

• SpringWorks Therapeutics Receives FDA Fast Track Designation for Nirogacestat for the Treatment of Adult Patients with Desmoid Tumors

  11/7/2018

  SpringWorks Therapeutics today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for nirogacestat, an investigational, oral, small molecule, selective gamma-secretase inhibitor, for the treatment of adult patients with progressive, unresectable, recurrent or refractory desmoid tumors or deep fibromatosis.

• SpringWorks Therapeutics Receives FDA Orphan Drug Designation for MEK Inhibitor (PD-0325901) for the Treatment of Neurofibromatosis Type 1

  11/5/2018

  SpringWorks Therapeutics today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug designation for PD-0325901, an investigational, oral, small molecule selective inhibitor of MEK1 and MEK2, for the treatment neurofibromatosis type 1.

• 

  Chinese Pharma Companies Continue to Shake Hands With Western Partners

  10/12/2018

  Brii Biosciences is one of many China-based companies that are heavily investing in U.S. biotech and pharmaceutical companies to support the development of programs that could come back to China for approval.
• 

  Not Just Pocket Change: China's Hillhouse Capital's New Fund Has $10.6 Billion to Invest

  9/20/2018

  China’s Hillhouse Capital Group, an equity investment firm, has a new fund, Hillhouse Fund IV, with $10.6 billion ready to invest.
• 

  R&D Cooperation Between China and Western Pharma Companies Up 70 Percent

  9/14/2018

  Without a doubt China has become one of the most important markets for pharma companies, given the vast patient population and the rising cancer rates. And it seems that western pharmaceutical companies are making greater inroads there.
• 

  Movers and Shakers for Sept. 10

  9/10/2018

  Let's take a look at who made a splash in the pharma and biotech world the past week.

• BeiGene and SpringWorks Therapeutics Enter into Global Clinical Collaboration to Evaluate Targeted Combination Therapy in Advanced Solid Tumors

  9/6/2018

  BeiGene’s RAF dimer inhibitor lifirafenib (BGB-283) and SpringWorks Therapeutics’ MEK inhibitor PD-0325901 to be studied in combination

• 

  China’s Beigene Teams up With Springworks to Target Advanced Solid Tumors

  9/6/2018

  SpringWorks Therapeutics and BeiGene, Ltd. have teamed up to develop therapeutics that will target advanced solid tumors that contain RAS mutations, as well as other MAPK aberrations.

• SpringWorks Therapeutics Announces Appointment of Saqib Islam as Chief Executive Officer

  9/5/2018

  Company Expands Management Team with Experienced Biotech Leaders

• SpringWorks Therapeutics to Present at Cowen and Company’s 38th Annual Health Care Conference

  3/5/2018

  SpringWorks Therapeutics, a mission-driven medicines company dedicated to developing innovative potential new treatments for underserved patient communities, today announced that the Company will present at the Cowen and Company 38th Annual Health Care Conference.

• Pfizer Spins Off 4 of Its Best Drug Candidates Into a Startup With $103 Million

  9/27/2017